(RLAY) Relay Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.925m USD | Total Return: 447.6% in 12m

Stock Oncology Drugs, Genetic Drugs, Protein Inhibitors, Drug Discovery
Total Rating 62
Safety 80
Buy Signal 0.94
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 1,925m
Avg Trading Vol: 20.0M USD
ATR: 7.21%
Peers RS (IBD): 91.3
Risk 5d forecast
Volatility67.3%
Rel. Tail Risk-10.6%
Reward TTM
Sharpe Ratio2.17
Alpha240.15
Character TTM
Beta1.515
Beta Downside0.643
Drawdowns 3y
Max DD89.05%
CAGR/Max DD-0.18
EPS (Earnings per Share) EPS (Earnings per Share) of RLAY over the last years for every Quarter: "2021-03": -0.47, "2021-06": -2.1, "2021-09": -0.66, "2021-12": -0.62, "2022-03": -0.57, "2022-06": -0.71, "2022-09": -0.76, "2022-12": -0.56, "2023-03": -0.78, "2023-06": -0.81, "2023-09": -0.54, "2023-12": -0.67, "2024-03": -0.62, "2024-06": -0.69, "2024-09": -0.63, "2024-12": -0.45, "2025-03": -0.4554, "2025-06": -0.41, "2025-09": -0.43, "2025-12": -0.32, "2026-03": 0,
EPS CAGR: 57.29%
EPS Trend: 80.7%
Last SUE: 4.00
Qual. Beats: 2
Revenue Revenue of RLAY over the last years for every Quarter: 2021-03: 0.952, 2021-06: 0.844, 2021-09: 0.666, 2021-12: 0.567, 2022-03: 0.419, 2022-06: 0.365, 2022-09: 0.344, 2022-12: 0.253, 2023-03: 0.226, 2023-06: 0.119, 2023-09: 25.202, 2023-12: -0.001, 2024-03: 10.007, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 7.679, 2025-06: 0.677, 2025-09: 0, 2025-12: 7, 2026-03: null,
Rev. CAGR: 111.89%
Rev. Trend: 23.0%
Last SUE: 0.78
Qual. Beats: 0
Risks
Technicals: volatile
Description: RLAY Relay Therapeutics

Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision medicines. The company utilizes a drug discovery platform centered on small molecule therapeutics for oncology and genetic diseases. This approach is common in the biotechnology sector, where research and development drive value.

Key product candidates include RLY-2608 for breast cancer and other solid tumors, and aGal chaperone for Fabry disease. The company also develops RLY-8161 and RLY-1013 for oncology targets, and lirafugratinib (RLY-4008) for cancer treatment. Strategic collaborations with entities like D. E. Shaw Research, Elevar Therapeutics, and Pfizer Inc. support its pipeline development, a typical strategy for funding and de-risking drug development in the pharmaceutical industry.

Understanding the specifics of these drug candidates and partnerships can provide deeper insights into Relay Therapeutics potential.

Headlines to Watch Out For
  • Clinical trial results for RLY-2608 significantly impact stock valuation
  • Regulatory approvals for pipeline drugs drive future revenue
  • Collaboration agreements with Pfizer and Elevar provide funding
  • Research and development expenses influence profitability
  • Competition in oncology and genetic disease markets affects market share
Piotroski VR‑10 (Strict) 1.0
Net Income: -276.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.38 > 0.02 and ΔFCF/TA -9.14 > 1.0
NWC/Revenue: 3.60k% < 20% (prev 7.58k%; Δ -3.98k% < -1%)
CFO/TA -0.38 > 3% & CFO -235.5m > Net Income -276.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 22.61 > 1.5 & < 3
Outstanding Shares: last quarter (171.6m) vs 12m ago 2.54% < -2%
Gross Margin: 84.70% > 18% (prev 0.45%; Δ 8.42k% > 0.5%)
Asset Turnover: 2.06% > 50% (prev 1.15%; Δ 0.91% > 0%)
Interest Coverage Ratio: -20.37 > 6 (EBITDA TTM -290.8m / Interest Expense TTM -14.3m)
Altman Z'' -15.00
A: 0.89 (Total Current Assets 578.3m - Total Current Liabilities 25.6m) / Total Assets 621.3m
B: -3.24 (Retained Earnings -2.01b / Total Assets 621.3m)
C: -0.39 (EBIT TTM -290.8m / Avg Total Assets 746.3m)
D: -37.11 (Book Value of Equity -2.01b / Total Liabilities 54.3m)
Altman-Z'' Score: -46.32 = D
Beneish M
DSRI: none (Receivables none/none, Revenue 15.4m/10.0m)
GMI: 0.54 (GM 84.70% / 45.40%)
AQI: 0.42 (AQ_t 0.00 / AQ_t-1 0.01)
SGI: 1.53 (Revenue 15.4m / 10.0m)
TATA: -0.07 (NI -276.5m - CFO -235.5m) / TA 621.3m)
Beneish M-Score: cannot calculate (missing components)
What is the price of RLAY shares? As of April 05, 2026, the stock is trading at USD 9.95 with a total of 2,178,687 shares traded.
Over the past week, the price has changed by +30.62%, over one month by +27.31%, over three months by +59.54% and over the past year by +447.60%.
Is RLAY a buy, sell or hold? Relay Therapeutics has received a consensus analysts rating of 4.31. Therefore, it is recommended to buy RLAY.
  • StrongBuy: 6
  • Buy: 5
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the RLAY price?
Wallstreet Target Price 17.1 71.8%
Analysts Target Price 17.1 71.8%
RLAY Fundamental Data Overview as of 04 April 2026
P/S = 125.3583
P/B = 3.1345
Revenue TTM = 15.4m USD
EBIT TTM = -290.8m USD
EBITDA TTM = -290.8m USD
Long Term Debt = 32.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.77m USD (from shortTermDebt, last quarter)
Debt = 32.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -51.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.40b USD (1.92b + Debt 32.5m - CCE 554.5m)
Interest Coverage Ratio = -20.37 (Ebit TTM -290.8m / Interest Expense TTM -14.3m)
EV/FCF = -5.95x (Enterprise Value 1.40b / FCF TTM -235.9m)
FCF Yield = -16.81% (FCF TTM -235.9m / Enterprise Value 1.40b)
 FCF Margin = -1.54k% (FCF TTM -235.9m / Revenue TTM 15.4m)
 Net Margin = -1.80k% (Net Income TTM -276.5m / Revenue TTM 15.4m)
 Gross Margin = 84.70% ((Revenue TTM 15.4m - Cost of Revenue TTM 2.35m) / Revenue TTM)
Gross Margin QoQ = 91.44% (prev none%)
Tobins Q-Ratio = 2.26 (Enterprise Value 1.40b / Total Assets 621.3m)
Interest Expense / Debt = 21.38% (Interest Expense 6.94m / Debt 32.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -229.7m (EBIT -290.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.61 (Total Current Assets 578.3m / Total Current Liabilities 25.6m)
Debt / Equity = 0.06 (Debt 32.5m / totalStockholderEquity, last quarter 567.1m)
 Debt / EBITDA = 0.18 (negative EBITDA) (Net Debt -51.6m / EBITDA -290.8m)
 Debt / FCF = 0.22 (negative FCF - burning cash) (Net Debt -51.6m / FCF TTM -235.9m)
 Total Stockholder Equity = 640.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.05% (Net Income -276.5m / Total Assets 621.3m)
RoE = -43.17% (Net Income TTM -276.5m / Total Stockholder Equity 640.4m)
RoCE = -43.21% (EBIT -290.8m / Capital Employed (Equity 640.4m + L.T.Debt 32.5m))
 RoIC = -35.87% (negative operating profit) (NOPAT -229.7m / Invested Capital 640.4m)
 WACC = 11.40% (E(1.92b)/V(1.96b) * Re(11.31%) + D(32.5m)/V(1.96b) * Rd(21.38%) * (1-Tc(0.21)))
Discount Rate = 11.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 18.31%
 [DCF] Fair Price = unknown (Cash Flow -235.9m)
 EPS Correlation: 80.66 | EPS CAGR: 57.29% | SUE: 4.0 | # QB: 2
Revenue Correlation: 23.01 | Revenue CAGR: 111.9% | SUE: 0.78 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.38 | Chg7d=+0.009 | Chg30d=+0.055 | Revisions Net=+6 | Analysts=8
EPS current Year (2026-12-31): EPS=-1.53 | Chg7d=+0.036 | Chg30d=+0.102 | Revisions Net=+2 | Growth EPS=+4.8% | Growth Revenue=-65.4%
EPS next Year (2027-12-31): EPS=-1.55 | Chg7d=+0.000 | Chg30d=+0.306 | Revisions Net=+1 | Growth EPS=-1.0% | Growth Revenue=+260.7%
[Analyst] Revisions Ratio: +1.00 (6 Up / 0 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle